Nateglinide does not reduce the incidence of diabetes or cardiovascular outcomes in people with impaired glucose tolerance and cardiovascular disease or risk factors

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)7-8
Number of pages2
JournalEvidence-Based Medicine
Volume16
Issue number1
DOIs
Publication statusPublished - Feb 2011

ASJC Scopus subject areas

  • Medicine(all)

Cite this